The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
News|Articles|June 8, 2015
Sealing and Barrier Solutions with High-Performance Materials
Author(s)Pharmaceutical Technology Editors
Saint-Gobain Seals is featuring several sealing and polymer solutions at ACHEMA including the OmniSeal spring-energized seals for liquid chromatography and the Rulon wear components for pharmaceutical manufacturing equipment.
Advertisement
Saint-Gobain Seals is featuring several sealing and polymer solutions at ACHEMA including the OmniSeal spring-energized seals for liquid chromatography and the Rulon wear components for pharmaceutical manufacturing equipment.
OmniSeal is a high-performance spring-energized polymer seal capable of handling extreme service conditions. It is typically used where ultra-low friction, chemical compatibility, and extreme temperature are required.
The Rulon material is a family of proprietary, homogeneous materials mostly of PTFE based resins, engineered and developed with specific custom applications in mind. It includes a variety of high-performance bearings and components, which meet today's need for enhanced wear performance in a PTFE-based material. The Rulon material withstands a variety of harsh environments such as extreme dryness, cryogenic temperatures, water, steam, and hydrocarbon fuel.
Source:
Advertisement
Related to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
CPHI Milan Brings Back Leadership Summit as Supply Chain and Manufacturing Pressures Ramp Up
4
PharmTech Weekly Roundup—September 18, 2026
5